Renal denervation for resistant hypertension

Area of Science:

• Cardiovascular Medicine
• Nephrology
• Interventional Cardiology

Background:

• Resistant hypertension is a prevalent and challenging condition.
• Current treatments often fail to improve outcomes and reduce cardiovascular/renal risk.
• Renal sympathetic hyperactivity drives resistant hypertension, making renal denervation a potential therapeutic option.

Purpose of the Study:

• To evaluate the short- and long-term effects of renal denervation in resistant hypertension.
• Assessed clinical end points, including cardiovascular events, mortality, and kidney function.
• Examined potential adverse events related to the renal denervation procedure.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials (RCTs).
• Searched multiple databases (Cochrane, MEDLINE, EMBASE, ClinicalTrials.gov) up to February 2016.
• Compared renal denervation against standard therapy or sham procedures.

Main Results:

• Low-quality evidence indicates renal denervation does not reduce major cardiovascular events (myocardial infarction, stroke) or improve renal function.
• Moderate-quality evidence shows no significant effect on blood pressure (ambulatory or office-measured).
• Low-quality evidence suggests an increased risk of bradycardia episodes; other adverse events were comparable or not assessable.

Conclusions:

• Renal denervation lacks demonstrated efficacy for major cardiovascular events, renal function, or blood pressure control in resistant hypertension.
• The procedure is associated with an increased risk of bradycardia.
• Future trials require larger sample sizes, longer follow-up, and patient-centered outcomes to clarify renal denervation's utility.